Selective estrogen receptor modulators

Toremifene citrate (/ˈtɔərᵻmᵻfin/) is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body.

Broparestrol (INN) (brand names Acnestrol, Longestrol), also known as α-bromo-α,β-diphenyl-β-p-ethylphenylethylene (BDPE), is a synthetic, non-steroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that is or was used in Europe as a dermatological agent and for the treatment of breast cancer.

Tamoxifen (TMX), sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men.

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast.

Cyclofenil (INN, USAN, BAN) (brand names Fertodur, Ondonid, Ondogyne, Sexovid, and others) is a selective estrogen receptor modulator used as a gonadotropin stimulant which is marketed in Europe, South Korea, Mexico, and Brazil, among other countries.

Triphenylethylene (TPE) is a simple aromatic hydrocarbon that possesses weak estrogenic activity.

Clomifene (INN) or clomiphene (USAN) (originally marketed as Clomid and subsequently under many brand names) is a selective estrogen receptor modulator (SERM) of the triphenylethylene group.

Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss.

Bisphenol A (BPA) is an organic synthetic compound with the chemical formula (CH3)2C(C6H4OH)2 belonging to the group of diphenylmethane derivatives and bisphenols, with two hydroxyphenyl groups.

Phenytoin, sold under the brand name Dilantin among others, is an anti-seizure medication.

Idoxifene is a non-steroidal estrogen antagonist.

Acolbifene (INN) (developmental code names EM-652, SCH 57068) is a selective estrogen receptor modulator that, as of 2015, is in phase III clinical trials for the treatment of breast cancer.

Bazedoxifene, or bazedoxifene acetate, is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals.

Ormeloxifene (also known as centchroman) is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor.

2-Hydroxyestradiol (2-OH-E2), also known as estra-1,3,5(10)-triene-2,3,17β-triol, is an endogenous steroid, catechol estrogen, and metabolite of estradiol, as well as a positional isomer of estriol.

Chlorotrianisene (INN, USAN, BAN; brand names Tace, Estregur, Anisene, Clorotrisin, Merbentyl, Triagen, many others; also known as CTA; tri-p-anisylchloroethylene, TACE, or tris(p-methoxyphenyl)chloroethylene) is a synthetic, non-steroidal estrogen of the triphenylethylene group that was formerly used for the treatment of menopausal symptoms, estrogen deficiency, and prostate cancer before being discontinued.

Nafoxidine (INN) (developmental code names U-11,000A, NSC-70735), or nafoxidine hydrochloride (USAN), is a non-steroidal selective estrogen receptor modulator (SERM) or partial antiestrogen of the triphenylethylene group that was developed for the treatment of advanced breast cancer by Upjohn in the 1970s but was never marketed.

Lasofoxifene (INN) (brand name Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).

Afimoxifene, also known as 4-hydroxytamoxifen (4-OHT, 4-HT, OHTAM, others), is a selective estrogen receptor modulator and the active metabolite of tamoxifen.

Arzoxifene is a selective estrogen receptor modulator.

Anordrin (former developmental code name AF-53), also known as 2α,17α-diethynyl-A-nor-5α-androstane-2β,17β-diol dipropionate, is a synthetic, steroid-like estrogen that is used in China as a postcoital contraceptive.

Estrobin, also known as α,α-di(p-ethoxyphenyl)-β-phenylbromoethylene and commonly abbreviated as DBE, is a synthetic, non-steroidal estrogen of the triphenylethylene group that was never marketed.

Ethamoxytriphetol (developmental code name MER-25) is a synthetic, non-steroidal antiestrogen that was studied clinically in the late 1950s and early 1960s but was never marketed.

Trioxifene (LY-133,314) was a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor-alpha (ERα) and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer, but was abandoned.

Brilanestrant (INN) (developmental code names GDC-0810, ARN-810, RG-6046, RO-7056118) is a non-steroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) that was discovered by Aragon Pharmaceuticals and is under development by Genentech for the treatment of locally advanced or metastatic estrogen receptor (ER)-positive breast cancer.

Elacestrant (INN) (developmental code names RAD-1901, ER-306323) is a non-steroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) (described as a "SERM/SERD hybrid (SSH)") that was discovered by Eisai and is under development by Radius Health and Takeda for the treatment of menopausal vasomotor symptoms (hot flashes) and estrogen receptor (ER)-positive advanced breast cancer, as well as endometrial cancer and kidney cancer.